Clinical trial
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
NCT00448292 · Epix Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00448292 |
|---|---|
| Title | A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of PRX-00023 in Patients With Major Depressive Disorder. |
| Lead sponsor | Epix Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder (MDD) |
| Intervention type | Drug |
| Interventions | PRX-00023, Placebo for PRX-00023 |
| Enrollment | 330 |
| Start date | Mar 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Mar 16, 2007 |
| Last update posted | Nov 14, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: